Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
121,543,157
-
Total 13F shares
-
88,130,237
-
Share change
-
+8,458,114
-
Total reported value
-
$554,340,167
-
Put/Call ratio
-
20%
-
Price per share
-
$6.29
-
Number of holders
-
137
-
Value change
-
+$59,175,204
-
Number of buys
-
94
-
Number of sells
-
45
Institutional Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q1 2025
As of 31 Mar 2025,
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) was held by
137 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
88,130,237 shares.
The largest 10 holders included
NEA Management Company, LLC, Frazier Life Sciences Management, L.P., BlackRock, Inc., Rubric Capital Management LP, VANGUARD GROUP INC, Vivo Capital, LLC, MPM BIOIMPACT LLC, Octagon Capital Advisors LP, VIKING GLOBAL INVESTORS LP, and ARMISTICE CAPITAL, LLC.
This page lists
137
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.